Navigation Links
Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
Date:3/5/2008

lopment candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of gout. The Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancer patients and is being investigated for the treatment of inflammatory diseases. Ardea also is developing a next-generation NNRTI for HIV and a next-generation MEK inhibitor for both cancer and inflammatory diseases.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including the expected properties and benefits of RDEA806 and RDEA119 and its other compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
2. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
3. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
4. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
5. Ardea Biosciences Announces $40 Million Private Placement
6. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
7. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
8. Ardea Biosciences Announces Changes to Research Management
9. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
10. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
11. DARA BioSciences, Inc. Announces Appointment of New Director to Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 ... technologies such as the Bioruptor® and complete solutions ... system for chromatin immunoprecipitation, alleviating the need for ... and controls needed for ChIP of histones or ...
(Date:1/22/2015)...   GenoSpace , a precision medicine software company that has ... use of genomic, imaging and other biomedical data in research ... Munson , CEO of Aspera, an IBM Company, to its ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to welcome ...
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Bulletin Board: ACCP) announced today that it will make ... Conference to be held,November 10-12, 2008 at the New ... scheduled to speak on Tuesday, November 11, 2008 at ... and discuss the Company,s,product opportunities., The presentation will ...
... ROCKVILLE, Md., Nov. 6 EntreMed, Inc.,(Nasdaq: ... the treatment of cancer and inflammatory diseases, today,reported ... September 30,2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ), ... approximately $3,501,000,versus $3,520,000 for the comparable period a ...
... safety profile of Ranexa -, - Conference ... -, PALO ALTO, Calif., Nov. 6 ... that the U.S. Food and Drug,Administration (FDA) has ... extended-release tablets) for the treatment of,chronic angina. The ...
Cached Biology Technology:Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference 2EntreMed Reports Third Quarter 2008 Financial Results 2EntreMed Reports Third Quarter 2008 Financial Results 3EntreMed Reports Third Quarter 2008 Financial Results 4EntreMed Reports Third Quarter 2008 Financial Results 5FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 2FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 3FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 4FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 5
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today announced the ... ancestry of individuals from across the United States ... four hundred years ago, the United States ... different continents. This study illuminates how American history and the ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced today its ... confirm its adherence to current U.S. Food and Drug ... regulated smart device and smart phone application trials utilizing ... "HITLAB is determined to improve global healthcare ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Infectious Diseases (NIAID), part of the National Institutes ... $80 million for two new Regional Centers of ... (RCE). The grants to the University of California, ... the completion of a national network of academic ...
... with implications for pandemic influenza, a new study reports for ... virus can spread from poultry to humans. The research ... Infectious Diseases, now available online. , Crossing the species barrier ... virus with pandemic potential. Previous studies have focused on the ...
... problem of "super-bugs" - bacteria that have become resistant ... high rate of antibiotic prescribing in hospitals contributes to ... antibiotics, an even more important factor contributing to such ... access international medical journal PLoS Medicine, is the use ...
Cached Biology News:New NIAID grants strengthen national biodefense and emerging infectious diseases research network 2Less virulent strains of avian influenza can infect humans 2Agricultural antibiotic use contributes to 'super-bugs' in humans 2
... 400 unique human proteins on a ... proteins, a cross section of all ... for high-quality results. Additional control proteins ... high validity and reproducibility., ,UNIchip protein ...
...
... The benchmark for analytical performance ... ease-of-use and the ultimate in ... Varian 810-MS features include: ... optics minimize,interferences, providing reliable, routine, ...
... it uses a deep-UV deuterium bulb, which provides ... a shutter (controlled via a TTL signal or ... DH-2000 Deuterium Tungsten Halogen Light Source combines the ... sources in a single optical path. The combined-spectrum ...
Biology Products: